Understanding the precise role of PIPKIγ in pancreatic cancer and its cooperation with EGF signaling in the context of PDAC may enable development of ultimately better therapeutic strategies via suppression of PIPKIγ in combinaton with the use of EGFR inhibitors, tailored to the appropriate PDAC patient population. The gene discussed is EGF; the disease is familial pancreatic carcinoma.